MicroRNA-708 emerges as a potential candidate to target undruggable NRAS

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• RAS oncogenes, particularly KRAS, are frequently mutated in cancer, driving tumorigenesis.
• Targeted therapies for NRAS mutations remain an unmet need, despite their prevalence in melanoma and leukemia.
• NRAS mutations promote cancer cell proliferation, survival, and motility, contributing to tumor progression.

Purpose of the Study:

• To investigate miRNA-708 as a potential therapeutic agent targeting NRAS mutations.
• To develop miRNA-based precision medicine for NRAS mutation-driven cancers.
• To elucidate the mechanism by which miRNA-708 affects NRAS expression and downstream signaling.

Main Methods:

• Confirmation of NRAS as a direct target of miRNA-708.
• Overexpression of miRNA-708 in cancer cell lines with NRAS mutations (melanoma, leukemia, lung cancer).
• Assessment of NRAS protein levels, cell proliferation, apoptosis, and downstream signaling pathways (PI3K-AKT-mTOR, RAF-MEK-ERK).

Main Results:

• Overexpression of miRNA-708 significantly reduced NRAS protein levels in NRAS-mutated cell lines.
• This reduction led to suppressed cell proliferation, anchorage-independent growth, and increased apoptosis.
• Inhibition of NRAS-downstream signaling pathways was observed in cells overexpressing miRNA-708.
• miRNA-708 did not affect proliferation in cell lines with wild-type NRAS.

Conclusions:

• miRNA-708 demonstrates therapeutic potential for NRAS mutation-driven cancers.
• Direct depletion of NRAS by miRNA-708 inhibits downstream effectors and decelerates cancer progression.
• Small RNA-mediated precision medicine using miR-708 offers a promising new avenue for cancer treatment.